Pictet Asset Management has cut its holdings in Dutch biopharmaceutical firm NewAmsterdam Pharma by over 42%, as institutional investor activity and insider disposals signal growing scrutiny on the company’s valuation and pipeline development.
Pictet Asset Management Holding SA cut its stake in NewAmsterdam Pharma Company N.V. by 42.3% in the fourth quarter, according to a MarketBeat report based on the firm’s latest filing with the US Securities and Exchange Commission. The Swiss asset manager sold 546,028 shares and finished the period with 746,122 shares, worth about $26.17 million. Even after the reduction, the position still accounted for a small but notable slice of the company’s equity.
The move comes against a backdrop of heavy institutional interest in the Dutch biopharmaceutical group. MarketBeat data show that institutions own the vast majority of NewAmsterdam Pharma’s stock, with Capital World Investors, Jennison Associates and Wellington Management among the larger holders after increasing their positions in recent quarters. Other ownership trackers paint a similarly crowded shareholder register, underscoring how closely watched the company has become among specialist healthcare investors.
Trading activity by insiders has also been brisk. According to the same filing summary, chief executive Michael H. Davidson sold 443,707 shares in early March, while insider Johannes Jacob Piete Kastelein sold 104,467 shares later that month. The disposals followed a period in which insiders sold more than 1.1 million shares in total over 90 days, even as corporate insiders retained a meaningful ownership stake in the business.
NewAmsterdam Pharma, which is focused on cardiometabolic disease, is best known for its lead drug candidate obicetrapib, a CETP inhibitor being studied in several clinical programmes, including work aimed at lowering LDL cholesterol and a separate early-stage Alzheimer’s trial, according to company descriptions cited by StockAnalysis and MarketBeat. The shares closed at $28.56 on Friday, leaving the company with a market value of about $3.28 billion, below the $48 average target price compiled by MarketBeat and well under the stock’s 52-week high of $42.00.
Source Reference Map
Inspired by headline at: [1]
Sources by paragraph:
Source: Noah Wire Services
Noah Fact Check Pro
The draft above was created using the information available at the time the story first
emerged. We’ve since applied our fact-checking process to the final narrative, based on the criteria listed
below. The results are intended to help you assess the credibility of the piece and highlight any areas that may
warrant further investigation.
Freshness check
Score:
10
Notes:
The article is dated May 1, 2026, and reports on a recent filing with the US Securities and Exchange Commission, indicating timely and original content. No evidence of recycled news or outdated information was found.
Quotes check
Score:
10
Notes:
The article does not contain direct quotes, relying instead on factual reporting of financial data and events. No concerns regarding the use of unverified or reused quotes.
Source reliability
Score:
7
Notes:
The article originates from MarketBeat, a financial news platform that aggregates and reports on market data. While MarketBeat is known for its financial reporting, it is not a primary news source. The reliance on aggregated data from other sources may affect the independence and originality of the content.
Plausibility check
Score:
8
Notes:
The reported actions of Pictet Asset Management Holding SA, including the reduction of its stake in NewAmsterdam Pharma Company N.V., align with typical institutional investment activities. However, the article’s reliance on aggregated data without direct access to the original SEC filing raises questions about the depth and accuracy of the reporting.
Overall assessment
Verdict (FAIL, OPEN, PASS): PASS
Confidence (LOW, MEDIUM, HIGH): MEDIUM
Summary:
The article provides timely and original reporting on Pictet Asset Management Holding SA’s reduction of its stake in NewAmsterdam Pharma Company N.V., with no direct quotes and freely accessible content. However, the reliance on aggregated data from MarketBeat without direct access to the original SEC filing raises concerns about the depth and independence of the reporting. While the content is factual and the source is reputable, the lack of direct sourcing affects the overall confidence in the verification process.